ABCs of Stem Cell
Tuesday April 12
“ABCs of Stem Cell” presented by William Decker , PhD, Ratan D. Bhardwaj, MD, PhD, Doris A. Taylor, PhD, Katherine Y. King, MD, PhD, Silke Paust, PhD
Time: 9:00 am to 5pm
Regenerative medicine is offering an unprecedented opportunity to help rebuild and restore damaged organs like the brain.
- Examine human brain cells from the perspective of cellular turnover
- Identify opportunities to examine stem cell plasticity in pediatric populations
- Investigate the importance of epigenetic regulation in cellular reprogramming
10:55 – 11:10 Q&A
11:10 – 12:05
Katherine Y. King, MD, PhD
Understanding signals that regulate hematopoietic stem and progenitor cells, the source of all blood production, may reveal novel strategies to prevent or treat hematologic diseases include bone marrow failure and leukemia.
- Reveal effects of inflammatory signaling, including interferon gamma, on hematopoietic stem cells
- Identify mechanisms of hematopoietic stem cell depletion during chronic infection
- Consider therapeutic applications for inflammatory modulation of hematopoietic stem cell function
12:05 – 12:20 Q&A
12:20 – 2:00 Break for Lunch
2:00 – 2:55
William K. Decker, PhD
New Frontiers in Neural Restoration
Inflammatory Regulation of Hematopoietic Stem Cells
The Dendritic Cell as a Functional Immunologic Stem Cell: Role in Cancer
Methods previously employed to promote anticancer immunity have lacked critical signals required to generate immunity in a productive fashion including the use of platforms that have likely been counterproductive. Incorporation of class I and II antigenic homology within future platforms should generate more productive and durable anticancer responses.
- The immune system is capable of recognizing cancer as “foreign”.
- The immune system can be properly trained to control cancer when regulated in the appropriate fashion.
- Therapeutic strategies that mimic viral infection in multiple respects stimulate the most productive anticancer immune responses.
2:55 – 3:10 Q&A
3:10 – 4:05
Silke Paust, PhD
Humanized mouse models as an effective experimental system to develop and evaluate the efficacy of novel cancer immunotherapies.
Patient derived xenograft (PDX) solid tumor mouse models can be derived from a wide variety of cancers and enable the evaluations of immune exhaustion, tumor microenvironment composition and therapeutic efficacy in vivo.
- Introduce the PDX mode, with a specific focus on tumor associated cellular compositions, tumor and immune cell engraftment in PDX mice over time
- Identify markers of tumor-associated immune exhaustion
- Investigate experimental therapies to prevent or reverse immune exhaustion to cure solid tumors in PDX mice in vivo
4:05 – 4:20 Q&A
4:20 – 5:15
Doris A. Taylor, PhD
The advent of autologous solid organ replacement has arrived. There now exist many new technologies that will ultimately allow regeneration of immunologically-matched organs and alleviate the need both for cadaveric organs and the immunosuppressive regimens required to prevent rejection of allogeneic grafts.
- Increase awareness and understanding about ground-breaking new treatments for heart failure
- Provide a step-by-step approach whereby new technologies can be engineered to alleviate the burden of chronic disease
- Inspire graduate students and other trainees to pursue career interests in regenerative medicine research
5:15 – 5:30 Q&A
5:30 – 5:45 Closing Remarks